Retatrutide Dosage Guide
65/100 confidenceComplete guide to Retatrutide dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose per Injection
4 mg – 12 mg
Frequency
Once per week
Route
subcutaneous
Detailed Dosage Information
Phase 2 trial doses
0.5 mg, 4 mg, 8 mg, and 12 mg weekly.
The 12 mg dose produced maximum weight loss (28.7%).
Phase 3 trials are evaluating doses up to 12 mg.
Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks).
Final approved dosing not yet established — Phase 3 trials ongoing.
Administration Method
Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028.
Research Backing
Phase 2 trial (NEJM, Jastreboff et al. 2023): 28.7% weight loss at 48 weeks (12 mg). Phase 3 TRIUMPH program initiated 2024. Eli Lilly development pipeline.
Side Effects to Monitor
Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses.
Safety Considerations & Risks
Pre-approval medication — full safety profile not yet established. Thyroid C-cell tumor risk expected (class effect). Glucagon receptor activation raises theoretical concerns about hepatic glucose output in diabetic patients, though clinical data shows improved glycemic control. Muscle loss data not yet fully characterized. Long-term safety beyond 48 weeks unknown.